Apoptosis and viral hepatitis

Seminars in Liver Disease

Volumn 18, Issue 2, 1998, Pages 169-176

  Lau, Johnson Y N ^a,b,f   Xie, Xiaoming ^a   Lai, Michael M C ^c,d   Wu, P C ^e  

^a Section of Hepatobiliary Diseases   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; HBV; HCV; Pathology; Viral hepatitis

Indexed keywords

APOPTOSIS; ARTICLE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRUS HEPATITIS;

EID: 0031901163     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007152     Document Type: Article

References (69)

1. Patel T, Gores GJ. Apoptosis and hepatobiliary diseases. Hepatology 1995;21:1725-1741
2. Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol 1997;71:1739-1746
3. Smyth MJ, Trapani JA. Granzymes Exogenous proteinases that induce target cell apoptosis. Immunol Today 1995;16:202-206
4. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, et al. Fas and perform pathways as major mechanisms of T-cell mediated cytotoxicity. Science 1994;265:528-530
5. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370 650-653
6. Williams GT, Smith CA. Molecular regulation of apoptosis: Genetic controls on cell deaths. Cell 1993;74:777-779
7. Ryo K, Kamogawa Y, Ikeda I, Kimura T, Miyazono Y, Shimizu T, Nishikawa M, et al. Fas and FasL strongly expressed in liver of fulminant hepatitis patients [abstract]. Hepatology 1995;22:230A
8. Lau JYN, Alexander GJM, Alberti A. Viral hepatitis. Gut 1991; 5 S47-S62
9. Fang JWS, Gonzalez-Peralta RP, Gottschall JA, Davis GL, Gish RG, Mizokami M, Lau JYN. Hepatic expression of c-Fas and apoptosis in chronic hepatitis C virus (HCV) infection [abstract]. Hepatology 1994;20:251A
10. Hayashi P, Marrone A, Kleiner D, Conjeevaram H, Mahaney K, Hoofnagle JH, Sallie R. Hepatic apoptosis is chronic hepatitis C: Analysis by in situ terminal transferasc labeling (TdTL) [abstract]. Hepatology 1994;20:160A
11. Ueda K, Ganem D. Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. J Virol 1996;70: 1375-1383
12. Yang D, Faris R, Hixson D, Affigne S, Rogler CE. Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. J Virol 1996;70:6260-6268
13. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-1340
14. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987;84:6909-6913
15. Lau JYN, Davies SE, Bain VG, O'Grady JG, Alberti A, Alexander GJM, Williams R. High level expression of hepatitis B viral (HBV) antigen in fibrosing cholestatic hepatitis - evidence that HBV may be cytopathic in liver grafts. Gastroenterology 1992; 102:956-962
16. Chisari FV. Hepatitis B virus transgenic mice: Insights into the virus and disease. Hepatology 1995;22:1316-1325
17. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261-281
18. Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88:214-222
19. Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570
20. Missale G, Redeker A, Person J, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell response to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993;177:751-762
21. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570
22. Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-6603
23. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS. Acute excerbations of chronic type B hepatitis are accompanied by increased T cell response to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992;89:87-96
24. Nakamura K, Yuh K, Sugyo S, Shijo H, Kimura N, Okumura M. Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996;111:156-164
25. Mochizuki K, Hayashi N, Hiramatsu N, Katayama K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T. Fas antigen expression in liver tissue of patients with chronic hepatitis B. J Hepatol 1996;24:1-7.
26. Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV, HBsAg retention sensitizes the hepatocytes to injury by physiological concentrations of interferon-gamma. Hepatology 1992; 16:655-663
27. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158:5692-5697
28. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;2:409-413
29. Sheron N, Lau JYN, Daniels H, et al. Increased production of tumour necrosis factor alpha in chronic HBV infection. J Hepatol 1991;12:241-245
30. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M Tumour necrosis factor alpha production by peripheral mononuclear cells of patients with chronic liver disease. Hepatology 1989;10:769-773
31. Fang JWS, Sheu WW, Meager A, Lau JYN. Activation of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection. A J Castro 1996;91:748-753
32. Lau JYN, Sheron N, Kayhan KT, Alexander GJM, Williams R. Increased tumour necrosis factor-alpha receptor number in chronic hepatitis B virus (HBV) infection Hepatology 1991;14:44-50
33. Guilhot S, Miller T, Cornman G, Isom HC. Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus. Am J Pathol 1996;148:801-814
34. Su F, Schneider RJ Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc Natl Acad Sci USA 1997;94.8744-8749
35. Gilles PN, Fey G, Chisari FV Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 1992;66:3955-3960
36. Sheron N, Lau JYN, Daniels HM, Westeber G, Alexander GJM, Williams R. Tumour necrosis factor to treat chronic hepatitis B virus infection. Lancet 1990;336:321-322
37. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease-effects of interferon alfa therapy. N Engl J Med 1991;324:933-940
38. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, Kim SJ. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator-role in HBV pathogenesis. J Clin Invest 1996;97:388-395
39. Kakumu S, Ito Y, Takayanagi M, Yoshioka K, Wakita T, Ishikawa T, Higashi Y, Yang ZQ. Effect of recombinant human transforming factor beta 1 on immune responses in patients with chronic hepatitis B. Liver 1993;13:62-68
40. Kakumu S, Ito Y, Wakita T, Yoshioka K, Ishikawa T, Takayanagi M, Higashi Y, Yang ZQ. Effects of transforming growth factorbeta 1 against the inhibitory action of interferon on DNA synthesis and viral replication in hepatitis B virus DNA-transfected cell. J Med Virol 1992;38:62-66
41. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8: 1109-1117
42. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-47
43. Takada S, Kaneniwa N, Tsuchida N, Koike K. Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system Virology 1996;216:80-89
44. Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M. The hepatitis B virus X gene induces p53-mediated programmed cell death. Pro Natl Acad Sci USA 1997;94: 8162-8167
45. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, Hoeijmakers JHJ, Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995;55:6012-6016
46. Puisieux A, Ji J, Guillot C, Legros Y, Soussi T, Isselbacher K, Ozturk M. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci USA 1995;92:1342-1346
47. Gonzalez-Peralta RP, Lau JYN. Pathogenetic mechanisms for hepatocellular damage in chronic hepatitis C virus infection. Sem in Gastroent 1995;6:28-34
48. González-Peralta RP, Fang JWS, Davis GL, Gish RG, Wu PC, Mizokami M, Lau JYN. Immunopathobiology of chronic hepatitis C virus infection [abstract]. Hepatology 1994;20:232A
49. Onji M, Kikuchi Y, Kumon, Masumoto T, Ndano S, Kajino K, Horikee N, Ohia Y. Intrahepatic lymphocyte subpopulations and HLA class I expression by hepatocytes in chronic hepatitis C. Hepato-Gastroenterol 1992;39:340-343
50. Nelson DR, Lau JYN. Pathogenesis of chronic hepatitis C. Sem-inars in Liver Diseases 1997; 1:515-528
51. Botarelli P. Brunetto MR, Minutello MA. Calvo P. Unutmaz D. Wemer AJ. Choo QL, Shuster JR. Kuo G, Bonino F. Houghton M, Abrignani S. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993: 194.580-587
52. Ferrari C. Vallih A, Galati L. Penna A, Scaccagîia P, Giuberti T, Schianchi C, Missaie G, Marin MG. Fiaccadori F. T-cell re-sponse Io structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C infections. Hepatology 1994:19:286-295
53. Minutello MA, Pleri P. Unutmaz D, Censini S. Kuo G, Houghton M, Brunetto MR, Bonino F, Abrignani S. Compartmentalization of T lymphocytes to the site of disease: Intrahepatic CD4+ T cell specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993:178:17-25
54. Koziel MJ. Dudley D. Wong JT. et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992:149:3339-44
55. Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H, Nakamura I, Yazaki Y, Imawari M. HLA B44-restricted cyto-toxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993:18:1039-1044
56. Nelson DR, Marousis CG. Davis GL, Rice CM, Wong J, Houghton M, Lau JYN. The role of hepatitis C virus-specific cy-totoxic T-lymphocytes in chronic hepatitis C. J Immunol 1997,158:1473-1481
57. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994:19:1354-1359
58. Bhardwaj G. Ohno T, Gish RG, Lau JYN. In vivo activation of cytotoxic T-lymphocyte (CTL) pathways in HCV-related cirrho-sis-implications on imrnunopathogenesis [abstract]. Hepatology 1996:24:374A
59. Mita E, Hayashi N, Ito S, Takehara T, Hijioka T, Kasahara A, Fusamoto H, Kamada T. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994;204:468-474
60. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M. Perfroin. Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanism of hepatitis C virus-specific human CTL. J Immunol 1997;158:5283-5291
61. Ohno T, Bhardwaj G, Nelson DR, Marousis CG, Mizokami M, Lau JYN. HLA-A2-restricted HCV-specific CTLs recognizing A.A. 132-140 exert their cytolytic activity through Fas and perforin-mediated pathways in vitro [abstract]. Gastroenterology 1997;112:A1351
62. Lim HL, Nelson DR, Fang JWS, Qian KP, Davis GL, Shen LP, Urdea MS, Kolberg JA, Lau JYN. The tumor necrosis factor-α system in chronic hepatitis C. Hepatology 1994;20:251A
63. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321
64. Nelson DR, Gonzalez-Peralta RP, Qian KP, Xu YL, Marousis CG, Davis GL, Lau JYN. Transforming growth factor-β1 in chronic hepatitis C. J Viral Hepat 1997;4:29-35
65. Bhardwaj G, Ohno T, Gonzalez-Peralta RP, Lau JYN. Hepatic expression of bcl-2 in chronic HCV infection [abstract]. Hepalology 1996;24:375A
66. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996;226:176-182
67. Fujita T, Ishido S, Muramatsu S, Itoh M, Hotta H. Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Biochem Biophy Res Commun 1996;229:825-831
68. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization of Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997;229:68-76
69. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997;71:1301-1309